DelveInsight’s report, “Chronic Inflammatory Demyelinating Polyneuropathy Market Insight, Epidemiology, and Market Forecast–2036,” provides a comprehensive analysis of the Chronic Inflammatory Demyelinating Polyneuropathy landscape. The report delivers detailed insights into the disease, including historical and forecasted epidemiology, helping stakeholders understand diagnosed prevalence, patient burden, and market opportunities across key regions.

Additionally, it examines Chronic Inflammatory Demyelinating Polyneuropathy market dynamics, offering a thorough assessment of current treatment practices, unmet needs, and emerging therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and commercialization initiatives.

To know in detail about the Chronic Inflammatory Demyelinating Polyneuropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here;https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the Chronic Inflammatory Demyelinating Polyneuropathy Market Report

• The Chronic Inflammatory Demyelinating Polyneuropathy market size in the 7MM is projected to increase significantly by 2036, mainly due to the launch of upcoming therapies and improved diagnosis rates.

• The United States accounted for the highest market size among the 7MM in 2025.

• The diagnosed prevalent cases of Chronic Inflammatory Demyelinating Polyneuropathy are expected to increase during the forecast period driven by improved disease recognition and diagnostic advancements.

• The US accounted for a significant share of diagnosed prevalent cases across the 7MM.

• EU4 and the UK represented a substantial share of the total diagnosed prevalent cases, while Japan also contributed significantly to the patient population.

• Leading companies advancing the pipeline include Sanofi and Immunovant, with promising candidates such as Riliprubart and Batoclimab.

• Riliprubart is in Phase III development, positioning it as one of the most advanced emerging therapies.

• Batoclimab has demonstrated meaningful improvements in disability scores in Phase IIb studies.

Key Factors Driving the Chronic Inflammatory Demyelinating Polyneuropathy Market

• Rising Awareness and Earlier Diagnosis Rates: Increasing awareness of autoimmune neurological disorders, along with improved access to electrophysiological testing and neurology care, is enabling earlier and more accurate diagnosis. Improved recognition among healthcare professionals and patients is expected to expand the identified treatment-eligible population.

• High Unmet Need Driving Innovative Therapies: Limitations of existing therapies, including safety concerns and treatment dependency, continue to create substantial unmet need in the market. Current treatment options often require long-term administration, creating strong opportunities for novel targeted treatments.

• Regulatory Incentives Accelerating Pipeline Development: Supportive regulatory pathways and orphan drug incentives are encouraging research and development activities. These incentives are helping accelerate clinical advancement and attract investment into neurological disease pipelines.

• Severe Disease Burden Supporting Premium Pricing Potential: The chronic and disabling nature of the disease, combined with long-term treatment requirements and healthcare costs, supports premium pricing opportunities for effective therapies offering sustained clinical benefit.

Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis

• Current treatment focuses on immunomodulation using corticosteroids, intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), and plasma exchange. These therapies help manage symptoms and slow disease progression but do not always provide durable long-term remission.

• Subcutaneous immunoglobulin (SCIg) has emerged as a convenient alternative for maintenance therapy, offering home-based administration and improved patient quality of life. However, many patients still experience relapse or treatment dependency.

• The market represents a significant unmet need due to limitations in long-term efficacy, safety concerns, and the lack of curative therapies targeting the underlying immune-mediated pathology.

Get a Free sample for the Chronic Inflammatory Demyelinating Polyneuropathy Market Forecast, Size & Share Analysis Report: Chronic Inflammatory Demyelinating Polyneuropathy Market Forecast

Chronic Inflammatory Demyelinating Polyneuropathy Competitive Landscape

Key companies such as Sanofi and Immunovant are leading the pipeline with differentiated approaches that could transform future treatment options and create meaningful commercial opportunities.

• Riliprubart (Sanofi): Phase III monoclonal antibody targeting activated C1s in the complement pathway, designed to inhibit inflammatory mechanisms responsible for demyelination and nerve damage.

• Batoclimab (Immunovant): FcRn inhibitor designed to reduce IgG levels and prevent IgG-mediated inflammation, showing promising improvements in disability scores in clinical studies.

Discover more about therapies set to grab major Chronic Inflammatory Demyelinating Polyneuropathy market share @ Chronic Inflammatory Demyelinating Polyneuropathy Treatment Landscape

Recent Development in the Chronic Inflammatory Demyelinating Polyneuropathy Treatment Landscape:

• In June 2025, Sanofi reported that riliprubart received orphan drug designation in Japan for CIDP.

• In August 2024, Sanofi initiated a Phase III clinical study evaluating riliprubart versus IVIg in patients with CIDP.

• In March 2025, Immunovant reported positive topline results from the Phase IIb study of batoclimab in CIDP.

What is Chronic Inflammatory Demyelinating Polyneuropathy?

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune inflammatory disorder of the peripheral nerves and nerve roots characterized by immune-mediated damage to the myelin sheath. It leads to progressive motor and sensory deficits, including muscle weakness, numbness, and impaired coordination, often resulting in long-term disability.

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation:

The Chronic Inflammatory Demyelinating Polyneuropathy market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Chronic Inflammatory Demyelinating Polyneuropathy

• Gender-specific Cases of Chronic Inflammatory Demyelinating Polyneuropathy

• Diagnosed Prevalent Cases of Chronic Inflammatory Demyelinating Polyneuropathy in the US

• Diagnosed Prevalent Cases in EU4 and the UK

• Diagnosed Prevalent Cases in Japan

Download the report to understand which factors are driving Chronic Inflammatory Demyelinating Polyneuropathy epidemiology trends @ Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Forecast

Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Companies: Sanofi, Immunovant, and others

• Key Therapies: Riliprubart, Batoclimab, and others

• Market Dynamics: Drivers and Barriers

• Competitive Intelligence Analysis: SWOT, market entry strategies, reimbursement scenario

• Unmet Needs, KOL Views, Analyst Views, Market Access and Reimbursement

Table of Contents

1. Chronic Inflammatory Demyelinating Polyneuropathy Market Report Introduction

2. Executive Summary for Chronic Inflammatory Demyelinating Polyneuropathy

3. SWOT Analysis of Chronic Inflammatory Demyelinating Polyneuropathy

4. Chronic Inflammatory Demyelinating Polyneuropathy Patient Share (%) Overview at a Glance

5. Chronic Inflammatory Demyelinating Polyneuropathy Market Overview at a Glance

6. Chronic Inflammatory Demyelinating Polyneuropathy Background and Overview

7. Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Inflammatory Demyelinating Polyneuropathy

9. Chronic Inflammatory Demyelinating Polyneuropathy Current Treatment and Medical Practices

10. Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs

11. Chronic Inflammatory Demyelinating Polyneuropathy Emerging Therapies

12. Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook

13. Country-Wise Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis (2022–2036)

14. Chronic Inflammatory Demyelinating Polyneuropathy Market Access and Reimbursement of Therapies

15. Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers

16. Chronic Inflammatory Demyelinating Polyneuropathy Market Barriers

17. Chronic Inflammatory Demyelinating Polyneuropathy Appendix

18. Chronic Inflammatory Demyelinating Polyneuropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/